Phase i trial of sunitinib and gemcitabine in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 4, 2012, Pages 547-553

  Brell, Joanna M ^a   Krishnamurthi, Smitha S ^a   Rath, Linda ^a   Bokar, Joseph A ^a   Savvides, Panayiotis ^a   Gibbons, Joseph ^a   Cooney, Matthew M ^a   Meropol, Neal J ^a   Ivy, Percy ^b   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gemcitabine; Pancreatic cancer; Phase I; Sunitinib

Indexed keywords

GEMCITABINE; SUNITINIB;

ADENOID CYSTIC CARCINOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLEEDING; BREAST TUMOR; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERM CELL TUMOR; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LUNG NON SMALL CELL CANCER; MALE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE CARCINOMA OF UNKNOWN PRIMARY; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OSTEOSARCOMA; OVARY TUMOR; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYMOMA; THYMUS CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; UTERINE CERVIX TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRROLES;

EID: 84867582561     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1936-5     Document Type: Article

References (15)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
3. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D (2011) Randomized, placebo-controlled, phase III study of firstline oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29: 1997-2003
4. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1835-1842
5. Awasthi N, Schwarz MA, Schwarz RE (2011) Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 13: 597-604
6. Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M, Van Damme N (2009) Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol Rep 22:105-113
7. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745
8. Yoon CY, Lee JS, Kim BS, Jeong SJ, Hong SK, Byun SS, Lee SE (2011) Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol 52: 55-63
9. Pandya SS, Mier JW, McDermott DF, Cho DC (2011) Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int 108: E245-E249
10. Reck M, Frickhofen N, Cedres S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 70: 180-187
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966
12. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610
13. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622
14. Tran Cao HS, Bouvet M, Kaushal S, Keleman A, Romney E, Kim G, Fruehauf J, Imagawa DK, Hoffman RM, Katz MH (2010) Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther 9: 2068-2078
15. Bharthuar A, Pearce L, Litwin A, LeVea C, Kuvshinoff B, Iyer R (2009) Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP 10:523-527